Next Investors logo grey

MyFiziq technology identified as having applications in oncology


Published 22-JUN-2020 10:49 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

MyFiziq Limited (ASX: MYQ) informed the market on Monday that it has been successfully developing the extension into body surface area calculation and other serial measurements with a view to informing oncology therapy decisions and prevention measures.

The company has already developed and patented a proprietary dimensioning technology that enables its users to privately and accurately check, track, and assess their dimensions using only a smartphone.

This has proved to have wide ranging applications which has been a significant factor in the company being able to forge relationships across a wide range of industries as it teams up with third parties where its technology can be embodied in established programs and services.

MyFiziq’s Dr Amar El-Sallam has been working on a number of new and innovative measurements to be included into the application as it navigates further uses that can dramatically impact the sectors the company is working in.

On this note, new potential medical applications in areas of treatment dosing calculations are required by specialist physicians when assessing cancer patients’ systemic therapy dosage needs.

The ability to determine body surface area (BSA) accurately from a mobile device would be a significant step forward in assessing these calculations when working with cancer patients.

Health professionals see benefits in mobile BSA measuring

MyFiziq is collaborating with medical doctor and oncology researcher, Dr Kate Barrett (MD) to fully understand the best approaches in areas of clinical oncology, both in-hospital and through telemedicine.

Dr Barrett will be the first oncologist to be given access to the new technology for closed trials and assessment.

Commenting on these developments, Barrett said, ‘’Up to 80% of individuals with advanced cancer undergo weight loss and wasting, the signs and symptoms of which are seen as prognostic parameters in cancer patients.

‘’The ability to make accurate and consistent evaluations through a handheld device will simplify the process on several levels in clinical and preventative medicine.

‘’Not only will it be easier to track and document BSA calculations for chemotherapies, pain medications, and other supportive drugs across the healthcare team, it will enable an improved visualisation of individual trends to assist in prevention and readily support concerning changes.’’

Next Investors Image

Human trials imminent

MyFiziq has been successfully testing the process and expects to commence trials with real subjects over the next 60 days.

Commenting on the group’s progress in this area and management’s vision for the future, chief executive and co-founder Vlado Bosanac said, ‘’The MyFiziq technology is a very safe, private and convenient means of effectively checking for changes in a number of day-to-day situations.

‘’This new use for our technology has been a long-time vision of mine and Dr El-Sallam.

‘’This is something that could truly change the way medications are calculated for patients and their long-term care.’’

BSA plays a key role in several medical fields, including cancer chemotherapy, transplantology, burn treatment and toxicology.

It is often a major factor in the determination of the course of treatment and drug dosage, and a series of formulae to simplify the process have been developed.

Because easy-to-identify, yet general, body coefficient results of those formulae vary considerably, the question arises as to whether the choice of a formula is valid and safe for patients.

The MyFiziq technology has the potential to change the way these calculations are implemented and furthermore bring a higher level of efficiency and safety in patient care.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.